Last edition
News about "Hibsago bepirovirsen chronic hepatitis B"
US FDA Approves GSK's Hibsago for Chronic Hepatitis B
The US FDA has approved GSK’s Hibsago (bepirovirsen) is for chronic hepatitis B, with phase 3 data showing improved functional cure rates after 6 months of treatment.
Hibsago Bepirovirsen Chronic Hepatitis B | 23/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members